Navigation Links
Few Women at High Risk for Breast Cancer Take Tamoxifen
Date:2/11/2010

Study finds less than 1% use it as preventative; experts say drug has gotten 'bad rap'

THURSDAY, Feb. 11 (HealthDay News) -- Only a tiny fraction of women at high risk of developing breast cancer take tamoxifen to prevent the disease.

This news comes despite the fact that experts have known since 1998 that tamoxifen can cut the risk of developing breast cancer by almost 50 percent.

"This is not a surprise to me," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La., which was one of the sites enrolling women for the trial that led to the approval of using tamoxifen for breast cancer prevention.

"The drug is actually a very fine drug for breast cancer prevention, but it has gotten a bad rap," Brooks continued. "I don't think we have changed the paradigm of the fact that we can predict which women are at increased risk for this disease and we can do something to lower their risk short of prophylactic mastectomy, but I don't think the medical profession has been able to communicate well enough to women so that they can understand that taking medicine can lower their risk of cancer."

V. Craig Jordan, scientific director of the Lombardi Comprehensive Cancer Center at Georgetown University, who is considered the "father" of tamoxifen, agreed: "There has been so much negative publicity about tamoxifen. No good information is being provided. That doesn't help."

While people are relatively comfortable with the notion that blood pressure and cholesterol drugs can lower the risk of heart problems in people who feel perfectly healthy, this is still an alien concept in the cancer world, Brooks said.

In addition to being used to treat breast tumors, tamoxifen (Nolvadex) is approved to prevent breast cancer recurrences and to prevent tumors in women who have not yet been diagnosed with the disease.

These authors looked at data from 2000 and 2005 from a large national survey (including about 10,000 women for each year) to estimate how many women were using tamoxifen for primary prevention of breast cancer.

In 2000, only about 0.2 percent of U.S. women aged 40 to 79 took tamoxifen to prevent breast cancer. In 2005, the prevalence was even lower -- only 0.08 percent.

The data did not say specifically how many of the women taking tamoxifen were at high risk for breast tumors, said Andrew N. Freedman, senior author of the paper appearing in the February issue of Cancer Epidemiology, Biomarkers & Prevention, but "we probably could assume they were high-risk."

The authors could only speculate on why the numbers were so low.

"It may be that patients and their physicians do not think the benefits outweigh the risks. It could be that physicians are not getting education about use of the drug. It could be concerns about side effects or physicians reluctant to prescribe," said Freedman, who is chief of the clinical and translational epidemiology branch of the division of cancer control and population sciences at the U.S. National Cancer Institute.

One recent study found that worries about side effects are a major reason why high-risk women are unwilling to take tamoxifen.

Tamoxifen's side effects include hot flashes, endometrial cancer and blood clots. A newer agent, raloxifene (Evista), a sister drug to tamoxifen, might be an alternative for women concerned about the risk of endometrial cancer.

However, tamoxifen works for both invasive and noninvasive breast cancer while raloxifene works only for the former, Brooks said.

Also tamoxifen, said Jordan, "is the only game in town for premenopausal women."

In the end, though, the decision lies with each individual woman.

"I think that the use of tamoxifen for chemoprevention is something that is a very personal choice between the physician and patient, and depends on many, many factors," Freedman said.

More information

The U.S. National Cancer Institute has more on tamoxifen.



SOURCES: Andrew N. Freedman, Ph.D., chief, Clinical and Translational Epidemiology Branch, Division of Cancer Control and Population Sciences, U.S. National Cancer Institute, Bethesda, Md.; V. Craig Jordan, Ph.D., D.Sc., scientific director, Georgetown University Lombardi Comprehensive Cancer Center, Washington, D.C.; Jay Brooks, M.D., chairman, hematology/oncology, Ochsner Health System, Baton Rouge, La.; February 2010, Cancer Epidemiology, Biomarkers & Prevention


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Womens Dermatologic Society Marks 35th Anniversary with Release of Unprecedented Book of Wisdom and Inspiration
2. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
3. Cyndi Lauper, Lady Gaga Put Spotlight on Women and HIV
4. Womens Heart Disease Awareness Still Lacking
5. Diabetes drug ups risk for bone fractures in older women
6. Women More Likely to Fail Treatment for Atrial Fibrillation
7. LifestyleMom.com and the LifestyleMom Radio Cafe Aim to Help Women Create a Family Life and "Me Life" That They Truly Love
8. Company Invites Women to STOP PMS - Take the 10-Minute Challenge
9. Women with gout at greater risk of heart attack than men
10. Study finds higher risk of stillbirth in women with fibroids
11. Women Riders to Rev for a Cure at Daytona Bike Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... The American Board of Family Medicine's (ABFM) Board of Directors ... Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve in ... retirement at the end of 2018. Upon assuming the role of President and CEO ...
(Date:10/13/2017)... , ... October 13, 2017 ... ... of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ... on guideline updates for the primary prevention of cardiovascular diseases during the ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
Breaking Medicine Technology: